215 related articles for article (PubMed ID: 31634035)
21. Meningococcal vaccination: a discussion with all adolescents, whether college-bound or not.
Alderfer JT; Moran MM; Srivastava A; Isturiz RE
Postgrad Med; 2019 Nov; 131(8):551-554. PubMed ID: 31575310
[No Abstract] [Full Text] [Related]
22. Meningococcal serogroup B vaccination series initiation in the United States: A real-world claims data analysis.
Packnett ER; Zimmerman NM; Novy P; Morgan LC; Chime N; Ghaswalla P
Hum Vaccin Immunother; 2023 Dec; 19(1):2165382. PubMed ID: 36715008
[TBL] [Abstract][Full Text] [Related]
23. Meningococcal vaccination in patients with newly diagnosed asplenia in the United States.
Ghaswalla PK; Bengtson LGS; Marshall GS; Buikema AR; Bancroft T; Schladweiler KM; Koep E; Novy P; Hogea CS
Vaccine; 2021 Jan; 39(2):272-281. PubMed ID: 33309081
[TBL] [Abstract][Full Text] [Related]
24. Serum bactericidal activity against circulating and reference strains of meningococcal serogroup B in the United States: A review of the strain coverage of meningococcal serogroup B (MenB) vaccines in adolescents and young adults.
Presa J; Burman C; Tort MJ; Cane A; Bocchini JA
Hum Vaccin Immunother; 2023 Dec; 19(1):2212570. PubMed ID: 37257838
[TBL] [Abstract][Full Text] [Related]
25. Factors Associated With Receipt of Meningococcal B Vaccine Among United States Adolescents, National Immunization Survey-Teen, 2017-2018.
Hansen CE; Niccolai LM
J Adolesc Health; 2021 Nov; 69(5):769-773. PubMed ID: 34148798
[TBL] [Abstract][Full Text] [Related]
26. Potential Coverage of the 4CMenB Vaccine against Invasive Serogroup B
Mulhall RM; Bennett D; Cunney R; Borrow R; Lucidarme J; Findlow J; Jolley KA; Bray J; Maiden MCJ; Moschioni M; Serino L; Stella M; Medini D
mSphere; 2018 Aug; 3(4):. PubMed ID: 30135218
[No Abstract] [Full Text] [Related]
27. Perceptions and Knowledge About the MenB Vaccine Among Parents of High School Students.
Richardson E; Ryan KA; Lawrence RM; Harle CA; Young A; Livingston MD; Rawal A; Staras SAS
J Community Health; 2021 Aug; 46(4):808-816. PubMed ID: 33389475
[TBL] [Abstract][Full Text] [Related]
28. Summary of the NACI Statement on the Use of Bivalent Factor H Binding Protein Meningococcal Serogroup B (MenB-fHBP) Vaccine for the Prevention of Meningococcal B Disease.
Harrison R; Stirling R; Baclic O; Vaudry W
Can Commun Dis Rep; 2020 Feb; 46(2-3):36-39. PubMed ID: 32167082
[TBL] [Abstract][Full Text] [Related]
29. Evolving strategies for meningococcal vaccination in Europe: Overview and key determinants for current and future considerations.
Martinón-Torres F; Taha MK; Knuf M; Abbing-Karahagopian V; Pellegrini M; Bekkat-Berkani R; Abitbol V
Pathog Glob Health; 2022 Mar; 116(2):85-98. PubMed ID: 34569453
[TBL] [Abstract][Full Text] [Related]
30. Meningococcal B vaccination coverage among older adolescents in the United States.
La EM; Garbinsky D; Hunter S; Poston S; Novy P; Ghaswalla P
Vaccine; 2021 May; 39(19):2660-2667. PubMed ID: 33849722
[TBL] [Abstract][Full Text] [Related]
31. Serogroup A, C, W, and Y meningococcal disease in persons previously vaccinated with a serogroup ACWY meningococcal vaccine - United States, 2014-2018.
Blain AE; Reese HE; Marjuki H; Topaz N; Mbaeyi S; McNamara LA
Vaccine; 2021 Dec; 39(52):7541-7544. PubMed ID: 34802785
[TBL] [Abstract][Full Text] [Related]
32. A physician's guide to the 2-dose schedule of MenB-FHbp vaccine.
McDaniel A; Dempsey A; Srivastava A
Hum Vaccin Immunother; 2019; 15(11):2729-2737. PubMed ID: 30932730
[TBL] [Abstract][Full Text] [Related]
33. Clinical data supporting a 2-dose schedule of MenB-FHbp, a bivalent meningococcal serogroup B vaccine, in adolescents and young adults.
Beeslaar J; Absalon J; Balmer P; Srivastava A; Maansson R; York LJ; Perez JL
Vaccine; 2018 Jun; 36(28):4004-4013. PubMed ID: 29861182
[TBL] [Abstract][Full Text] [Related]
34. Whole genome analysis of Neisseria meningitidis isolates from invasive meningococcal disease collected in the Czech Republic over 28 years (1993-2020).
Honskus M; Krizova P; Okonji Z; Musilek M; Kozakova J
PLoS One; 2023; 18(3):e0282971. PubMed ID: 36913385
[TBL] [Abstract][Full Text] [Related]
35. National, Regional, State, and Selected Local Area Vaccination Coverage Among Adolescents Aged 13-17 Years - United States, 2019.
Elam-Evans LD; Yankey D; Singleton JA; Sterrett N; Markowitz LE; Williams CL; Fredua B; McNamara L; Stokley S
MMWR Morb Mortal Wkly Rep; 2020 Aug; 69(33):1109-1116. PubMed ID: 32817598
[TBL] [Abstract][Full Text] [Related]
36. Vaccines against Neisseria meningitidis serogroup B strains - What does genomics reveal on the Portuguese strain's coverage.
Bettencourt C; Nogueira P; Paulo Gomes J; João Simões M
Vaccine; 2022 Aug; 40(33):4772-4779. PubMed ID: 35778280
[TBL] [Abstract][Full Text] [Related]
37. Culture-Confirmed Invasive Meningococcal Disease in Canada, 2010 to 2014: Characterization of Serogroup B
Tsang RSW; Law DKS; De Paola R; Giuliani M; Stella M; Zhou J; Deng S; Boccadifuoco G; Giuliani MM; Serino L
mSphere; 2020 Mar; 5(2):. PubMed ID: 32132156
[TBL] [Abstract][Full Text] [Related]
38. Clinical experience with the meningococcal B vaccine, Bexsero(®): Prospects for reducing the burden of meningococcal serogroup B disease.
Watson PS; Turner DP
Vaccine; 2016 Feb; 34(7):875-80. PubMed ID: 26686570
[TBL] [Abstract][Full Text] [Related]
39. Recommendations for Serogroup B Meningococcal Vaccine for Persons 10 Years and Older.
COMMITTEE ON INFECTIOUS DISEASES
Pediatrics; 2016 Sep; 138(3):. PubMed ID: 27573083
[TBL] [Abstract][Full Text] [Related]
40. Effectiveness of Meningococcal Vaccines at Reducing Invasive Meningococcal Disease and Pharyngeal Neisseria meningitidis Carriage: A Systematic Review and Meta-analysis.
McMillan M; Chandrakumar A; Wang HLR; Clarke M; Sullivan TR; Andrews RM; Ramsay M; Marshall HS
Clin Infect Dis; 2021 Aug; 73(3):e609-e619. PubMed ID: 33212510
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
